Publications by authors named "Dalia Ercan"

21Publications

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Cancer Res 2015 Aug 5;75(15):3139-46. Epub 2015 Jun 5.

Lowe Center for Thoracic Oncology, Boston, Massachusetts. Department of Medical Oncology, Boston, Massachusetts. Department of Medicine, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3771DOI Listing
August 2015

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Clin Cancer Res 2015 Sep 6;21(17):3913-23. Epub 2015 May 6.

Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791951PMC
September 2015

Pharmacological targeting of the pseudokinase Her3.

Nat Chem Biol 2014 Dec 19;10(12):1006-12. Epub 2014 Oct 19.

1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Biological Chemistry &Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nchembio.1658DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232461PMC
December 2014

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.

Clin Cancer Res 2014 Dec 7;20(24):6551-8. Epub 2014 Oct 7.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1337DOI Listing
December 2014

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.

Mol Oncol 2015 Jan 29;9(1):260-9. Epub 2014 Aug 29.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.08.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528687PMC
January 2015

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

Cancer Res 2013 Jan 19;73(2):834-43. Epub 2012 Nov 19.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-12-2066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994895PMC
January 2013

Discovery of selective irreversible inhibitors for EGFR-T790M.

Bioorg Med Chem Lett 2011 Jan 10;21(2):638-43. Epub 2010 Dec 10.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.12.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035422PMC
January 2011